Journal of Bone and Mineral Research

New and Unexpected Roles for Primary Cilia in Coordinating Response to Mechanical Load in Articular and Growth Plate Cartilages.  37:1079-1080. 2022

Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment 2022

Racial and Ethnic Disparities in Bone Health and Outcomes in the United States.  36:1881-1905. 2021

Genome-wide Association Studies Reveal Novel Locus With Sex-/Therapy-Specific Fracture Risk Effects in Childhood Cancer Survivors.  36:685-695. 2021

Lung-Specific Risk Factors Associated With Incident Hip Fracture in Current and Former Smokers.  35:1952-1961. 2020

Secular Trends in the Incidence of Hip Fracture Among Nursing Home Residents.  35:1668-1675. 2020

Both NPY-Expressing and CART-Expressing Neurons Increase Energy Expenditure and Trabecular Bone Mass in Response to AP1 Antagonism, But Have Opposite Effects on Bone Resorption.  35:1107-1118. 2020

Reply to Serious Adverse Events With Romosozumab Use in Japanese Patients: Need for Clear Formulation of Contraindications Worldwide.  35:996-997. 2020

Temporal Trends and Factors Associated with Bisphosphonate Discontinuation and Restart.  35:478-487. 2020

American Society for Bone and Mineral Research-Orthopaedic Research Society Joint Task Force Report on Cell-Based Therapies.  35:3-17. 2020

Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition.  35:36-52. 2020

Specific RANK Cytoplasmic Motifs Drive Osteoclastogenesis.  34:1938-1951. 2019

The Design and Validation of a New Algorithm to Identify Incident Fractures in Administrative Claims Data.  34:1798-1807. 2019

ΔFosB Requires Galanin, but not Leptin, to Increase Bone Mass via the Hypothalamus, but both are needed to increase Energy expenditure.  34:1707-1720. 2019

Cost-Effectiveness of Osteoporosis Screening Using Biomechanical Computed Tomography for Patients With a Previous Abdominal CT.  34:1229-1239. 2019

Association of Dietary Niacin Intake With Incident Hip Fracture, BMD, and Body Composition: The Cardiovascular Health Study.  34:643-652. 2019

Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions.  33:1881-1888. 2018

Specificity Protein 7 Is Required for Proliferation and Differentiation of Ameloblasts and Odontoblasts.  33:1126-1140. 2018

Evaluation of a Multimodal, Direct-to-Patient Educational Intervention Targeting Barriers to Osteoporosis Care: A Randomized Clinical Trial.  33:763-772. 2018

Prevalence of Osteoporosis and Low Bone Mass Among Puerto Rican Older Adults.  33:396-403. 2018

The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical Trial.  32:2278-2287. 2017

Addressing the Crisis in the Treatment of Osteoporosis: A Path Forward.  32:424-430. 2017

Impact of Competing Risk of Mortality on Association of Weight Loss With Risk of Central Body Fractures in Older Men: A Prospective Cohort Study.  32:624-632. 2017

The Association Between Protein Intake by Source and Osteoporotic Fracture in Older Men: A Prospective Cohort Study.  32:592-600. 2017

Novel Genetic Variants Associated With Increased Vertebral Volumetric BMD, Reduced Vertebral Fracture Risk, and Increased Expression of SLC1A3 and EPHB2.  31:2085-2097. 2016

Risk Factors for Hip Fracture in Older Men: The Osteoporotic Fractures in Men Study (MrOS).  31:1810-1819. 2016

What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective Study.  31:1500-1503. 2016

Increase in Fracture Risk Following Unintentional Weight Loss in Postmenopausal Women: The Global Longitudinal Study of Osteoporosis in Women.  31:1466-1472. 2016

Wrist Fracture and Risk of Subsequent Fracture: Findings from the Women's Health Initiative Study.  30:2086-2095. 2015

Mendelian randomization analysis to examine for a causal effect of urate on bone mineral density.  30:985-991. 2015

Diagnosis and management of osteonecrosis of the jaw: A systematic review and international consensus.  30:3-23. 2015

Loss of Runx2 in committed osteoblasts impairs postnatal skeletogenesis.  30:71-82. 2015

Runx2 regulates endochondral ossification through control of chondrocyte proliferation and differentiation.  29:2653-2665. 2014

The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine.  29:2520-2526. 2014

Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: The global longitudinal study of osteoporosis in women (GLOW).  29:487-493. 2014

Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American society for bone and mineral research.  29:1-23. 2014

Risk factors for treatment failure with antiosteoporosis medication: The global longitudinal study of osteoporosis in women (GLOW).  29:260-267. 2014

A close examination of healthcare expenditures related to fractures.  28:816-820. 2013

A randomized trial of a mailed intervention and self-scheduling to improve osteoporosis screening in postmenopausal women.  27:2603-2610. 2012

Recent trends in hip fracture rates by race/ethnicity among older US adults.  27:2325-2332. 2012

Energy expenditure and bone formation share a common sensitivity to AP-1 transcription in the hypothalamus.  27:1649-1658. 2012

Serum response factor regulates bone formation via IGF-1 and Runx2 signals.  27:1659-1668. 2012

Central DXA utilization shifts from office-based to hospital-based settings among medicare beneficiaries in the wake of reimbursement changes.  27:858-864. 2012

Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: results from the Look AHEAD randomized trial..  27:619-627. 2012

Previous fractures at multiple sites increase the risk for subsequent fractures: The global longitudinal study of osteoporosis in women.  27:645-653. 2012

Predicting fractures in an international cohort using risk factor algorithms without BMD.  26:2770-2777. 2011

Serum 25-hydroxyvitamin D and clinical fracture risk in a multiethnic cohort of women: The women's health initiative (WHI).  26:2378-2388. 2011

Stronger bone correlates with African admixture in African-American women.  26:2307-2316. 2011

Effects of miR-335-5p in modulating osteogenic differentiation by specifically downregulating Wnt antagonist DKK1.  26:1953-1963. 2011

Erratum: Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the American Society for Bone and Mineral Research (Journal of Bone and Mineral Research (2010) 25 (2267-2294)).  26:1987. 2011

Nucleosides accelerate inflammatory osteolysis, acting as distinct innate immune activators.  26:1913-1925. 2011

APPswe/Aβ regulation of osteoclast activation and RAGE expression in an age-dependent manner.  26:1084-1098. 2011

The relationship between bisphosphonate adherence and fracture: Is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial.  26:683-688. 2011

Atypical subtrochanteric and diaphyseal femoral fractures: Report of a task force of the american society for bone and mineral Research.  25:2267-2294. 2010

Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US national osteoporosis foundation guidelines.  25:1506-1511. 2010

Tumor-derived syndecan-1 mediates distal cross-talk with bone that enhances osteoclastogenesis.  25:1295-1304. 2010

Candidate gene analysis of femoral neck trabecular and cortical volumetric bone mineral density in older men.  25:330-338. 2010

Ferritin ferroxidase activity: A potent inhibitor of osteogenesis.  25:164-172. 2010

Lower bone mass in prepubertal overweight children with prediabetes.  25:2760-2769. 2010

Serum 25-hydroxyvitamin D and the risk of hip and nonspine fractures in older men.  25:545-553. 2010

Health care expenditures associated with skeletal fractures among medicare beneficiaries, 1999-2005.  24:2050-2055. 2009

High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men.  24:2039-2049. 2009

Myeloma bone disease.  24:1783-1788. 2009

Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis.  24:1643-1646. 2009

Bridging the osteoporosis quality chasm.  24:3-7. 2009

Hormone therapy improves femur geometry among ethnically diverse postmenopausal participants in the women's health initiative hormone intervention trials.  23:1935-1945. 2008

A Runx2 Threshold for the Cleidocranial Dysplasia Phenotype..  23:S384-S384. 2008

Benefit of adherence with bisphosphonates depends on age and fracture type: Results from an analysis of 101,038 new bisphosphonate users.  23:1435-1441. 2008

Induction of Runx2 and Osterix by Bisphosphonate Promote Osteogenic Differentiation.  23:S257-S257. 2008

Calcium channel TRPV6 is involved in murine maternal-fetal calcium transport.  23:1249-1256. 2008

HMGB1 regulates RANKL-induced osteoclastogenesis in a manner dependent on RAGE.  23:1084-1096. 2008

Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005.  23:1061-1067. 2008

Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling.  23:596-609. 2008

Doubly truncated FosB isoform (Δ2ΔFosB) induces osteosclerosis in transgenic mice and modulates expression and phosphorylation of Smads in osteoblasts independent of intrinsic AP-1 activity.  23:584-595. 2008

Genetic and pharmacologic activation of the hypoxia inducible factor pathway promotes angiogenesis and accelerates bone regeneration.  22:S19-S19. 2007

Growth inhibition of osteoblast progenitors by Runx2 depends on its C-terminal regulatory domain and is accompanied by changes in G-Protein coupled signaling pathways.  22:S94-S94. 2007

Marked disturbance of calcium homeostasis in mice with targeted disruption of the Trpv6 calcium channel gene.  22:274-285. 2007

Predictors of non-spine fracture in elderly men: The MrOS study.  22:211-219. 2007

Krüppel-like zinc finger protein Glis3 promotes osteoblast differentiation by regulating FGF18 expression.  22:1234-1244. 2007

Defects in intranuclear localization of Runx2 alter osteoblast differentiation ex vivo..  21:S155-S155. 2006

Mitotic retention of the bone phenotype by the cell fate determining transcription factor Runx2..  21:S378-S378. 2006

Post-mitotic expression of transcription factor RUNX2 defines a novel regulatory transition during the G1 phase of proliferating Pre-Osteoblasts..  21:S384-S384. 2006

Specific residues of Runx2/Cbfa1 direct Osteoblast differentiation and integration of BMP2 osteogenic signal..  21:S381-S381. 2006

Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: Results from the women's health initiative randomized trial.  21:817-828. 2006

RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.  20:107-116. 2005

RhoA and cytoskeletal disruption mediate reduced osteoblastogenesis and enhanced adipogenesis of human mesenchymal stem cells in modeled microgravity.  20:1858-1866. 2005

A critical point mutation in the Runx2 subnuclear targeting domain abrogates osteogenic function by blocking integration of the BMP2 signal.  20:S9-S9. 2005

Inactivation of Nek1 protein kinase signaling in Kat2J mice leads to skeletal defects..  20:S40-S40. 2005

Microarray analysis of differential gene expression in OSCC cell lines..  20:S213-S213. 2005

Msx2 antagonizes Runx2 regulation of osteolytic activity in breast cancer cells..  20:S327-S327. 2005

Reconstitution of Runx2/Cbfa1null cells identifies Runx2 domains required for osteoblast differentiation.  20:S5-S5. 2005

Runx2 association with microtubules: A potential role in nucleo-cytoplasmic shuttling..  20:S78-S78. 2005

The Runx2 transcription factor supports expression of genes coupled to the invasive and osteolytic properties of breast cancer cells..  20:S328-S328. 2005

Comparative effect of soy protein, soy isoflavones, and 17β-estradiol on bone metabolism in adult ovariectomized rats.  20:828-839. 2005

Contributions of nuclear structure-function relationships to the onset and progression of tumorigenesis.  20:P7-P7. 2005

Expression patterns of matrix metalloproteinases and vascular endothelial growth factor during epiphyseal ossification.  20:1011-1021. 2005

RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts..  20:107-116. 2005

Runx2 regulates tumor cell invasive properties and contributes to the osteolytic bone disease associated with metastatic cancer cells.  20:P16-P16. 2005

Runx2/Msx2 interactions regulating breast cancer-induced osteolysis in bone.  20:P33-P33. 2005

Convergence of BMP2/TGF beta MAPK and Runx2 signaling in subnuclear foci during osteogenic lineage induction.  19:S46-S46. 2004

Dlx3 is a transcriptional regulator of osteoblast differentiation and increases expression and promoter activity of Runx2..  19:S37-S37. 2004

Establishment of a mechanistic link between the osteogenic function of Runx2 and its sulnuclear organization by intranuclear informatics..  19:S144-S144. 2004

Expression pattern of core binding factor-beta in skeletal tissues.  19:S400-S400. 2004

Multiple nuclei in osteoclasts functionally compartmentalize gene regulatory machinery.  19:S280-S281. 2004

Wnt signaling regulates Runx2 expression in vivo and activates the bone-related Runx2 P1 promoter.  19:S56-S56. 2004

Ectopic Runx2 regulates breast cancer metastasis-associated osteolytic disease.  19:1578-1578. 2004

Chromatin remodeling of the proximal rat osteocalcin promoter is dependent on vitamin D receptor binding at the distal promoter element.  18:S225-S225. 2003

Ectopic runx2 regulates breast cancer metastasis associated osteolytic disease.  18:S26-S26. 2003

Subnuclear targeting supports functional interrelationships between Runx2 and the BMP-2 regulated Smad 1 protein.  18:S6-S7. 2003

Radioguided Parathyroidectomy for Recurrent Hyperparathyroidism Caused by Forearm Graft Hyperplasia.  18:939-942. 2003

Cbfb, a well-known, regulator of hematopoiesis, cooperates with Cbfa1 and plays a critical role in bone development..  17:S126-S126. 2002

Runx factors are expressed in the osteoclast and regulated during osteoclast differentiation..  17:S452-S452. 2002

Runx1(Cbfa2/AML1) is expressed in tissues supporting osteogenesis and temporally regulated during chondrocyte and osteoblast differentiation..  17:S151-S151. 2002

Genome screen for quantitative trait loci contributing to normal variation in bone mineral density: The Framingham study.  17:1718-1727. 2002

Radioguided parathyroidectomy via VATS combined with intraoperative parathyroid hormone testing: The surgical approach of choice for patients with mediastinal parathyroid adenomas?.  17:1368-1371. 2002

Developmental utilization of distinct promoters regulating the type I and type II isoforms of the bone Runx2/Cbfa1 transcription factor..  16:S205-S205. 2001

Forced expression of Runx2/Cbfa1 driven by the -3.6 kb Collagen Type I promoter results in a normal phenotype in transgenic mice..  16:S446-S446. 2001

Runx2-C/EBP molecular interactions and functional synergism support maximal expression of osteocalcin in osteoblasts..  16:S175-S175. 2001

Trafficking of Runx1/Cbfa2 and Runx2/Cbfa1 in living cells defines a dynamic subnuclear domain..  16:S488-S488. 2001

Acidic fibroblast growth factor signaling inhibits peroxynitrite-induced death of osteoblasts and osteoblast precursors.  16:1917-1925. 2001

The loss of Smad3 results in a lower rate of bone formation and osteopenia through dysregulation of osteoblast differentiation and apoptosis.  16:1754-1764. 2001

Validation of peripheral dual-energy X-ray absorptiometry for the measurement of bone mineral in intact and excised long bones of rats.  16:1682-1687. 2001

C/EBP is a potent activator of osteocalcin gene transcription..  15:S497-S497. 2000

In vivo replacement of the Runx2/Cbfa1 gene with a mutant gene lacking a subnuclear targeting signal and transcriptional regulatory functions results in severe skeletal abnormalities..  15:S157-S157. 2000

RUNX (CBFalpha/AML/PEBP2alpha) dependent repression of tissue-specific gene transcription involves in situ association with Groucho/TLE/R-esp proteins..  15:S498-S498. 2000

Rapid epiphyseal trabecular bone resorption in high-dose corticosteroid treatment correlates with osteocytic apoptosis and passive tetracycline uptake, while cytokine expression patterns in vitro implicate an alternative osteoclast induction mechanism..  15:S542-S542. 2000

C/EBP family members are expressed in osteoblast and are involved in regulation of osteocalcin gene transcription..  14:S469-S469. 1999

Cbfa family members act as a negative regulator of the bone sialoprotein gene..  14:S165-S165. 1999

Contributions of nuclear architecture to bone-specific and steroid hormone regulation of osteocalcin gene transcription..  14:S454-S454. 1999

Resorption and microfractures precede vascular changes in subarticular bone with high-dose glucocorticoid treatment..  14:S547-S547. 1999

Structure-function determinants for subnuclear targeting and transactivation in the Cbfa1/AML3 transcription factor..  14:S469-S469. 1999

The C-terminus of CBFA1 supports subnuclear trafficking of green fluorescent protein tagged-CBFA1..  14:S553-S553. 1999

Analysis of osteocalcin expression in transgenic mice reveals a species difference in vitamin D regulation of mouse and human osteocalcin genes.  12:1570-1576. 1997

Expression of nitric oxide synthase isoforms in bone and bone cell cultures.  12:1108-1115. 1997

The BsmI vitamin D receptor restriction fragment length polymorphism (bb) influences the effect of calcium intake on bone mineral density.  12:1049-1057. 1997

A comparative immunocytochemical study on the subcellular distributions of 44 kDa bone phosphoprotein and bone γ‐carboxyglutamic acid (Gla)‐containing protein in osteoblasts.  2:337-346. 1987

Mechanism of fibroblast attachment to bone extracellular matrix: Role of a 44 kilodalton bone phosphoprotein.  2:259-265. 1987